Vertex Pharmaceuticals - M&A Summary and Business Overview

Life ScienceCompany

Vertex Pharmaceuticals M&A Summary

Vertex Pharmaceuticals has acquired 8 companies, including 5 in the last 5 years. A total of 1 acquisition came from private equity firms. It has also divested 2 assets.

Vertex Pharmaceuticals’ largest acquisition to date was in 2024, when it acquired Alpine Immune Sciences for $4.9B. It’s largest disclosed sale occurred in 2013, when it sold INCIVO to Janssen Pharmaceuticals for $152M. Vertex Pharmaceuticals has acquired in 3 different US states, and 2 countries. The Company’s most targeted sectors include life science (100%).

Vertex Pharmaceuticals Business Overview

Where is Vertex Pharmaceuticals headquartered?

Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

What is Vertex Pharmaceuticals’ revenue?

Vertex Pharmaceuticals disclosed revenue of 9,869M USD for 2023 and 8,931M USD for 2022.

How many employees does Vertex Pharmaceuticals have?

Vertex Pharmaceuticals has 5,400 employees.

What sector is Vertex Pharmaceuticals in?

Vertex Pharmaceuticals is a life science company.

When was Vertex Pharmaceuticals founded?

Vertex Pharmaceuticals was founded in 1989.

M&A Summary

  • M&A Total Activity10
    • M&A Buy Activity8
    • M&A Sell Activity2
  • Total Sectors Invested 1
  • Total Countries Invested 2
  • M&A Buy/Sell Connections 4
  • M&A Advisors 2

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc.

50 Northern Avenue,
Boston, Massachusetts 02210
United States,
(617) 341-6100
www.vrtx.com

Vertex Pharmaceuticals is a biotechnology company that aims to discover, develop, and commercialize innovative new medicines so people with serious diseases can lead better lives. Vertex Pharmaceuticals was founded in 1989 and is based in Boston, Massachusetts.


M&A Summary

Buy vs Sell

Year ≤ '19 '20 '21 '22 '23 '24 T
Buy (0.6/yr) # 5 - - 2 - 1 8
vol $3.1B $60M $4.9B $8.0B
Sell (0.0/yr) # 2 - - - - - 2
vol $152M $152M
  10

Most Recent M&A

Company Date Value Type
Alpine Immune Sciences, Inc. 2024-04-10 4.9B USD Add-on Acquisition
Seattle, Washington · www.alpineimmunesciences.com
ViaCyte, Inc. 2022-07-11 - Add-on Acquisition
San Diego, California · www.viacyte.com
Catalyst Biosciences - Protease Medicines 2022-05-23 60M USD Divestiture
San Francisco, California
Semma Therapeutics, Inc. 2019-09-03 950M USD Add-on Acquisition
Cambridge, Massachusetts · www.semma-tx.com
Exonics Therapeutics, Inc. 2019-06-06 1.0B USD Add-on Acquisition
Watertown, Massachusetts · www.exonicstx.com
Concert Pharmaceuticals, Inc. - CTP-656 2017-03-06 160M USD Divestiture
Lexington, Massachusetts
Vertex Pharmaceuticals - Lomibuvir & Merimepodib Inhibitors 2016-07-26 - Divestiture
Boston, Massachusetts
INCIVO 2013-11-20 152M USD Divestiture
, United States · www.incivo.com
ViroChem Pharma, Inc. 2009-03-12 375M USD Add-on Acquisition
Laval, Quebec · www.virochempharma.com
Aurora Biosciences Corp. 2001-07-18 592M USD Add-on Acquisition
San Diego, California · www.aurorabio.com
View All >>

M&A by Sector

Sector Buy # Value Sell # Value
Life Science 8 (100%) 8.0B (100%) 2 (100%) 152M (100%)
Total 8 $8.0B 2 $152M

By Geo

State/Country Buy Value Sell Value
United States 7 7.7B 2 152M
  Massachusetts 3 2.1B 1 -
  California 3 652M - -
  Washington 1 4.9B - -
Canada 1 375M - -
  Quebec 1 375M - -
Domestic 7 (88%) 7.7B (95%) 2 (100%) 152M (100%)
Cross-border 1 (13%) 375M (5%) - -
Total 8 $8.0B 2 $152M

Top M&A Advisors

Financial Deals
Lazard
1
Legal Deals
Skadden, Arps, Slate, Meagher & Flom
1

Deal Values

buy # Total
> $1B 2 $5.9B
$100M to $1B 4 $2.1B
< $100M 1 $60M
TOTAL $8.0B
Largest Alpine Immune Sciences, Inc.
$4.9B (2024-04-10)
sell # Total
$100M to $1B 1 $152M
TOTAL $152M
Largest INCIVO
$152M (2013-11-20)

M&A Connections

Deals
Acquired from
Investor(s)
13%
1 (13%)
Strategic(s)
13%
1 (13%)
Divested to
Strategic(s)
100%
2 (100%)

 Subscribe to unlock this and 209,130
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 202K M&A Transactions
  • 205K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.